Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hookipa Pharma Inc (NQ: HOOK )

0.6625 +0.0825 (+14.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,254,650
Open 0.5900
Bid (Size) 0.6500 (1)
Ask (Size) 0.6780 (1)
Prev. Close 0.5800
Today's Range 0.5800 - 0.6900
52wk Range 0.4100 - 1.779
Shares Outstanding 21,588,756
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire

Performance

YTD
-17.19%
-17.19%
1 Month
+48.61%
+48.61%
3 Month
-3.34%
-3.34%
6 Month
-38.08%
-38.08%
1 Year
-17.19%
-17.19%

More News

Read More
Earnings Preview For HOOKIPA Pharma
Via Benzinga
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Analyst Ratings for HOOKIPA Pharma
Via Benzinga
What 4 Analyst Ratings Have To Say About HOOKIPA Pharma
Via Benzinga
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Announces Executive Leadership Change
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
7 Biotech Stocks to Sell in September Before They Crash & Burn
Via InvestorPlace
HOOKIPA Pharma to participate in upcoming investor conferences in September
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
1847 Holdings And 3 Other Stocks Under $1 Insiders Are Buying
Via Benzinga
TeraWulf And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
CURO Group And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
HOOKIPA Pharma And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.